Trial Profile
Planned phase II trial of LOR 253 + docetaxel in patients with non-small cell lung cancer.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 24 Dec 2021
Price :
$35
*
At a glance
- Drugs APTO 253 (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 20 Dec 2021 Status changed from planning to withdrawn prior to enrolment because company decided to discontinue further clinical development of APTO-253. The decision follows prioritization of the company's other more advanced pipeline candidates, as well as an internal review of the product profile and performance to date of APTO-253, including a clinical hold placed by the U.S. Food & Drug Administration, according to an Aptose Biosciences media release.
- 10 Jul 2013 New trial record